Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor Cell Antigen Recognition by Autologous Cytotoxic T Cell Receptor on Tumor-Infiltrating Lymphocytes (TIL TCR-Antigen Recognition)
- Target
- TIL TCR-Antigen Recognition
- Molecular classification
- T Cell Receptor (TCR), Receptor, MHC Class I, HLA Class I, Antigen Presentation
01
Overview
The process by which autologous cytotoxic T lymphocytes (CTLs) infiltrating a tumor (tumor-infiltrating lymphocytes, or TILs) recognize and bind to antigens presented on the surface of tumor cells via their T cell receptors (TCRs). This recognition event triggers CTL activation and targeted killing of tumor cells. This process can be therapeutically harnessed using adoptive cell therapy and other immunotherapeutic strategies.
- Other names
- Autologous TCR-Antigen InteractionTumor-Infiltrating Lymphocyte TCR RecognitionCTL TCR-Tumor Antigen RecognitionTIL TCR-mediated Tumor Cell Killing
02
Mechanism of action
Specific recognition of tumor-associated antigens presented on MHC class I by autologous TCR, leading to T cell activation and cytotoxic killing of tumor cells.
03
Biological functions
T cell activationAntigen recognitionTumor cell killingAdaptive immune responseCytotoxicityImmune surveillance
04
Disease associations
CancerTumor immunologyImmune evasion
05
Safety considerations
On-target, off-tumor toxicityCytokine release syndrome (CRS)Graft-versus-host disease (GvHD) in allogeneic settingsTumor lysis syndromeImmune-related adverse events (irAEs)
06
Interacting drugs
Adoptive cell therapies (ACT)
2 more in the full profile.
07
Biomarkers
TCR clonality within TILsExpression of target antigen on tumor cellsMHC-I expression on tumor cellsCD8+ T cell infiltrationIFN-gamma production upon TCR stimulationTumor mutational burden (TMB)
Beyond the preview
Go deeper on Tumor Cell Antigen Recognition by Autologous Cytotoxic T Cell Receptor on Tumor-Infiltrating Lymphocytes (TIL TCR-Antigen Recognition).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor Cell Antigen Recognition by Autologous Cytotoxic T Cell Receptor on Tumor-Infiltrating Lymphocytes (TIL TCR-Antigen Recognition).